The raw sequences have been submitted to NCBI under Bioproject accession number SUB4205063 - Bioproject number: PRJNA477950.

Introduction {#sec001}
============

The domestic water buffalo (*Bubalus bubalis*) contributes to a significant share of global milk production and is the major milk producing animal in several countries, such as India and Pakistan \[[@pone.0210204.ref001]\]. Water buffaloes are resistant to most of the disease affecting dairy cows, even in a context of low feeding and environmental stress \[[@pone.0210204.ref002]--[@pone.0210204.ref004]\]. The background of this resistance lies in mammary gland anatomical features, including a long narrow teat canal, a teat skin less sensitive to chapping and sores, a streak canal with thicker epithelium and keratin layer, a tighter sphincter of streak canal and the absence of milk cistern \[[@pone.0210204.ref005]\]. These distinct features of the buffalo mammary gland are believed to prevent the invasion of micro-organisms. The few studies on water buffalo mastitis presented the evidence that somatic cell score in quarters with intramammary infection is low, and a limited decrease in milk production was found among infected animals as compared to healthy ones \[[@pone.0210204.ref006]\]. However, mastitis is still occurring in dairy buffaloes in intensive dairy farming \[[@pone.0210204.ref007]\], with an impact that might be comparable to that of dairy cows concerning production losses, culling and treatment costs \[[@pone.0210204.ref008]\], beside decreasing animal health and welfare \[[@pone.0210204.ref009],[@pone.0210204.ref010]\].

The conventional therapy against mastitis includes the treatment of the mammary gland with antibiotics. Although necessary for both therapeutic and prophylactic purposes, treatment with antibiotics is not fully efficient, and presents several drawbacks. The extended use of antibiotics is at the background of the development of anti-microbial resistance that can persist in the bacterial community \[[@pone.0210204.ref011], [@pone.0210204.ref012]\], as demonstrated for *Streptococcus agalactiae* \[[@pone.0210204.ref013]\] and *Staphylococcus aureus* \[[@pone.0210204.ref014]\]. Furthermore, the massive use of antibiotics in dairy animals is at the origin of antibiotic residues' pollution in the environment and contamination of milk and other animal-derived products, causing antibiotic resistance in humans as well \[[@pone.0210204.ref015]\].

Alternative strategies are investigated, aiming to reduce the use of antibiotics. New therapeutic approaches, such as, among the others, Generally Recognized As Safe (GRAS) bacteria, including Lactic Acid Bacteria (LAB), have been developed \[[@pone.0210204.ref016]\]. The *in vitro* and *in vivo* effects of treatment with LAB produced different and opposite results in cows. *In vitro* studies on the effects of *Lactococcus lactis* as potential anti-mastitis therapeutics have shown promising results on bovine mammary epithelial cells by producing nisin A, a polycyclic antibacterial peptide \[[@pone.0210204.ref017]\]. The different strains of lactobacilli that have been investigated so far included *Lactobacillus perolens*, *Lactobacllus rhamnosus*, *Lactobacillus brevis* and *Lactobacillus plantarum* \[[@pone.0210204.ref018]--[@pone.0210204.ref021]\]. *In vitro* results were encouraging, and an overall reduction of bacterial load together with an anti-inflammatory activity were demonstrated. On the contrary, the *in vivo* use of GRAS produced contradictory results and their activity remains inconclusive. *Lactococcus lactis* stimulates the intramammary immune system of cattle, as determined by polymorphonuclear cells (PMN) recruitment and increasing of haptoglobin and serum amyloid A concentrations in milk \[[@pone.0210204.ref022]\]. Nonetheless, only in few studies the live cultures of *Lactococcus lactis* were effective in bovine mastitis treatment \[[@pone.0210204.ref023]\]. In a model of mouse mastitis, the experimental infection with *Staphylococcus chromogenes* and treatment with live cultures of *Lactococcus lactis* induced an increased level of IL-1β and TNFα, in addition to tissues damages, suggesting that these GRAS strains cannot be used for mastitis treatment in rodents. Recent findings on ewes affected by subclinical mastitis confirmed that the infusion of *Lactococcus lactis* into the mammary gland leads to a transient clearance of the pathogens, but also increases the inflammatory status of the mammary gland \[[@pone.0210204.ref024]\]. Similarly, treatment with different strains of *Lactobacillus* failed to decrease cow mastitis and caused a local inflammatory response \[[@pone.0210204.ref025],[@pone.0210204.ref026]\]. Among GRAS, *Lactobacillus rhamnosus* was found to possess the strongest antibacterial activity against *Salmonella enterica* \[[@pone.0210204.ref027]\], and also capable of preventing the *Escherichia coli*--induced changes in epithelial barrier functions \[[@pone.0210204.ref028]\]. Similar results were demonstrated in cows as well, where the potential of *Lactobacillus rhamnosus* against *Escherichia coli*-infection in vagina and endometrium \[[@pone.0210204.ref029],[@pone.0210204.ref030]\], intestine \[[@pone.0210204.ref031]\] and respiratory apparatus \[[@pone.0210204.ref032]\] was also reported. Information about the activity of *Lactobacillus rhamnosus* on mammary gland is, one the contrary, very limited. *In vitro* studies provided evidence that *Lactobacilus rhamnosus* pretreatment was able to attenuate the pro-inflammatory effects of an *E*.*coli* challenge on primary bovine mammary epithelial cells by suppressing TLR and inflammasome related gene expression \[[@pone.0210204.ref033],[@pone.0210204.ref034]\]. To the best of the knowledge of the authors, no study was carried out to investigate the *in vivo* effects of *Lactobacillus rhamnosus* in the mammary gland, in particular for what concerns how *Lactobacillus* treatment can influence the delicate equilibrium between bacterial communities.

Culture-independent techniques relying on high-throughput DNA sequencing of 16S provided an in-depth knowledge of bacterial communities, and are currently applied to unravel the relationship between resident microbial population and the development of mastitis\[[@pone.0210204.ref035]--[@pone.0210204.ref038]\]. The results of these studies demonstrated that bacterial species are present in culture-negative samples collected from animals with clinical mastitis \[[@pone.0210204.ref039]\] and that major pathogens, such as *Streptococcus uberis* and *Staphylococcus aureus*, can be found in milk from clinically healthy animals \[[@pone.0210204.ref035]\]. On this background, the insurgency of mastitis may be related to both the presence of specific pathogen and the modification of the microbial community of milk \[[@pone.0210204.ref040]\]. This observation was confirmed in water buffalo, whose milk microbiota has been recently published \[[@pone.0210204.ref041]\].

The aim of this study was to investigate the effect of an intramammary inoculation of *Lactobacillus rhamnosus* on the milk SCC and microbiota of water buffaloes naturally affected by sub-clinical mastitis. The effect of antibiotics, that were also used as positive control for anti-bacterial activity on milk microbiota, were characterized as well. *Lactobacillus rhamnosus* was selected on the background of its *in vitro* antibacterial activity in the epithelial mammary gland cellular model.

Materials and methods {#sec002}
=====================

Bacterial strain, culture conditions and inactivation of *Lactobacillus rhamnosus* inocula {#sec003}
------------------------------------------------------------------------------------------

The probiotic *Lactobacillus rhamnosus* strain GG (LMG 18243) from the BCCM/LMG Bacteria Collection (Belgium) was prepared as follows: the bacterium was grown at 37°C for 48h in Trypticase Soy Broth (TSB, BD, Italy) in a Gaspak jar using the commercial gas-generating AnaeroGen AN25 kit (Oxoid, England) for anaerobic growth. The probiotic culture was then centrifuged at 3000 x g for 20 min, washed twice with sterile pyrogen-free saline solution (NaCl 0.9%) and suspended in the solution used for the inoculum, namely sterile PBS (Sigma-Aldrich, Milano). This bacterial suspension (approximately 10^9^ CFU x mL^-1^) was inactivated after boiling at 100°C for 15 min. The absence of viable cells was verified by culturing on TBS medium. Five mL of the heat-inactivated suspension were used for each intramammary injection.

Study design and intramammary challenge {#sec004}
---------------------------------------

The experimental protocol was approved by Italian Ministry of Health (Protocol No.982/2015PR). The study was carried out on 20 multiparous water buffaloes (*Bubalus bubalis*) homogeneous for parity (2^nd^ to 4^th^ lactation) and in mid lactation (from 60 to 160 DIM). The animals were housed in a commercial farm and left 29 days to become familiar with the experimental conditions. During that time, animal health status was diagnosed clinically and quarter milk samples were collected for bacteriological analysis and Somatic Cell Count (SCC).

For the purpose of this study, quarters affected by sub-clinical mastitis were defined as those with no evidence of clinical signs, but positive to microbiological culture for three times before T0 (included). Following these criteria, a total number of 43 samples were included in the study as affected by sub-clinical mastitis. Milk samples were collected weekly at T-29, T-21, T-15, T-7 and T0 and then intramammary inoculated following this protocol: at T0, 15 quarters were inoculated with 5 ml of inactivated cultures of *Lactobacillus rhamnosus* (LAB) (LAB-T0), 11 quarters were inoculated with amoxicillin-clavulanic acid (Synulox Lactating Cow Intramammary Suspension, Pfizer, Italy) (Ab-T0), and 17 quarters were inoculated with 5 ml of sterile PBS (Sigma-Aldrich, Milano) (PBS-T0). After challenging, samples of milk were further collected at time T1, T2 and T6.

Milk samples were collected after disinfection of teat ends with a 2% povidone-iodine (Betadine Solution) and discarding of the first three strains of milk. Gloves were changed each time and 150 ml of milk were collected in sterile containers. After collection, milk samples were immediately refrigerated and delivered to the laboratory for microbiological analysis and SCC. Milk samples were finally aliquoted and stored at -80 C for microbiota identification, which was carried out on milk samples at T0 and T6.

Clinical observation and animal care {#sec005}
------------------------------------

Clinical signs were monitored throughout the experiment by a veterinary practitioner, every 8 hours during the first 24 hours from the challenge and then every time the water buffaloes were milked. Rectal temperature was measured every 24 hours. General attitude, and appetite were evaluated, and the udders were palpated to identify soreness, swelling hardness and heat, to assess the development of clinical signs.

Microbiological culture (MC) and Somatic Cell Count (SCC) {#sec006}
---------------------------------------------------------

Microbiological culture tests were performed for each milk sample using different media as previously reported \[[@pone.0210204.ref041]\]. Briefly, samples were incubated at 37° for 24h in aerobic conditions on Trypticase soy agar (with 5% sheep blood), MacConkey agar and Baird Parker agar; at 37° for 72h in aerobic conditions on Prototheca isolation medium (PIM); at 37° in microaerobic conditions on Mycoplasma agar. Gram staining, coagulase and oxidase tests were performed on cultures with mastitis pathogens; in particular, in *Staphylococcus* spp. positive culture were tested for coagulase activity using rabbit plasma, and *Streptococcus* spp positive cultures were evaluated with Streptokit-BioMérieux test for Lancefield grouping. Somatic cell count was measured in milk samples at T-29, T-21, T-15, T-7, T0, T1, T2, and T6 (days) using Fossomatic (Foss) apparatus by means of the UNI EN ISO 13366--2:2007 technique for electronic optical fluorimetric counters.

DNA extraction {#sec007}
--------------

One ml of milk was centrifuged at room temperature at 16,100 rcf \[[@pone.0210204.ref036],[@pone.0210204.ref041]\]. Fat and supernatant were discarded and the remaining pellet was resuspended with 250ul of the Power Bead Tube of the DNEasy Power Soil Kit (QIAGEN) used to extract bacterial DNA, according to the manufacturer's instructions. After the DNA elution in 50 μl of DNAse and RNAse free water, DNA concentration and purity were analysed using NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Weltham, Massachusetts, U.S.A.) at wavelength 230, 260 and 280 nm and DNA samples were stored at -80° until further processing. The reagents included in the kit, without any bacterial DNA, were used as blank control for each DNA extraction batch.

Amplification of the hypervariable V4 region of bacterial 16S rRNA gene by PCR and barcoding {#sec008}
--------------------------------------------------------------------------------------------

V4 region of 16S rRNA gene was amplified for each sample \[[@pone.0210204.ref037]\]. The forward primer was `5’–CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNNNNNNGATGTGYCAGCMGCCGCGGTAA– 3’`, composed of the adapter linker, the key, the barcode, different for each sample, and the forward primer 515F. The reverse primer was `5’–CCTCTCTATGGGCAGTCGGTGATGGACTACNVGGGTWTCTAAT– 3’`, composed of the adapter linker and the R806 reverse primer. The Thermo Scientific Phusion Hot Start II High-Fidelity DNA polymerase kit was used to perform V4 PCR; each PCR reaction contained RNAse and DNAse free water, 5x Phusion Buffer HF (5 μl), dNTPs 2mM (2.5 μl), Primer Fw 10μM (1.25 μl), Primer Rv 10μM (1.75 μl), Phusion High Fidelity Taq Polymerase 2 U/μl (0.25 μl) and 5 ng of DNA. When DNA samples quantification was too low (less than 5 ng/μl), 5 μl of the samples were used to perform PCR. The thermal profile consisted of an initial denaturation of 30 sec at 98°C, followed by 32 cycles of 15 sec at °98 C, 15 sec at 50°C, 20 sec at 72°C, and a final extension of 7 min at 72°C. Each PCR plate included samples derived from each group. After DNA purification using Agencourt AMPure XP kit with a ratio 1:1, quality and quantity of PCR products were determined using Agilent Bioanalyser 2100 and Qubit fluorometer.

For 17 samples showing DNA concentration lower than 1 ng/μl at Qubit quantification, PCR was repeated using the same PCR condition and increasing the number of cycles up to 36. The lack of amplification of extraction and PCR negative controls was confirmed for all PCR.

Next-generation sequencing, bioinformatics and statistical analysis {#sec009}
-------------------------------------------------------------------

Sequencing was performed using Ion Torrent Personal Genome Machine (PGM) with the Ion 318 Chip Kit v2 (Thermo Fisher Scientific, Weltham, Massachusetts, U.S.A.), by the Centre for Research in Agricultural Genomics (CRAG, Bellaterra, Barcelona), following manufacturer's instructions. The raw sequences have been submitted to NCBI under Bioproject accession number SUB4205063---Bioproject number: PRJNA477950. After sequencing, reads were demultiplexed in order to have sequence file for each barcode/sample and Primer Rv was removed. Then, sequences were imported in the Quantitative Insight Into Microbial Ecology 2 (QIIME 2) software \[[@pone.0210204.ref042]\] ([https://qiime2.org](https://qiime2.org/)), which was used to analyze data. After obtaining a unique file with all sequencing data, DADA2 was used as quality filtering method in order to denoise, dereplicate single-end sequences and remove chimeras \[[@pone.0210204.ref043]\]. Afterward, the primer Fw was removed and a truncation length of 245 bases was used, taking into account the quality plot result and the mean V4 length of around 250 bases. After that, the units of observation, composed of unique sequences namely Amplicon Sequence Varians (ASVs), were used to classify them and assign taxonomy, using Greengenes 13.8 \[[@pone.0210204.ref044]\] at 99% of Operational Taxonomic Units (OTUs) identity and trimmed to V4 region, as reference database. Finally, chloroplasts were removed from the sequences.

The filtered feature table was used to perform the downstream analysis. The taxonomic analysis was performed for each sample or group of samples at phylum, family and genus level. Diversity analysis was assessed using 9500 sequences per sample. Alpha diversity that analyses differences within samples was performed using qualitative and quantitative approaches (richness or Observed species and evenness or Shannon index, respectively); beta diversity that analyzes differences among samples estimating how many taxa are shared among samples, was performed using qualitative and quantitative approaches as well (unweighted and weighted UniFrac distances matrices, respectively).

As data presented in this study were not-normally distributed and composed of pre- and post-treatment samples (T0 vs T6 within the same group), non-parametric paired test was applied. To compare the effect of the treatment on the microbiota (PBS-T6 vs LAB-T6; PBS-T6 vs Ab-T6; LAB-T6 vs Ab-T6), non-parametric unpaired test was applied. Taxonomic statistical analysis was performed using Wilcoxon signed pairwise test (pairwise.wilcox.test in coin package) and Kruskal Wallis test followed by Dunn pairwise test (dunn.test package) in R version 3.4.3 ([http://www.R-project.org](http://www.r-project.org/)), for paired and unpaired comparisons, respectively. A specific QIIME 2 plugin for longitudinal studies was used for alpha diversity and beta diversity principal coordinates analyses: as two time points were considered for this experiment, Wilcoxon rank sum pairwise test was used for paired data, while Kruskal Wallis and Wilcoxon Mann-Whitney U pairwise test were applied for unpaired data \[[@pone.0210204.ref045]\]. Workflow details are available at [dx.doi.org/10.17504/protocols.io.ucpesvn](http://dx.doi.org/10.17504/protocols.io.ucpesvn).

Results {#sec010}
=======

Diagnosis of sub-clinical mastitis, intramammary inoculation of inactivated *Lactobacillus rhamnosus*, collection of samples {#sec011}
----------------------------------------------------------------------------------------------------------------------------

The diagnosis of sub-clinical mastitis was carried out according to microbiological culture results and SCC. None of the animals included in this study evidenced any clinical signs related to the development of an acute mastitis. Results of microbiological culture are presented in Tables [1](#pone.0210204.t001){ref-type="table"} and [S1](#pone.0210204.s001){ref-type="supplementary-material"} showing that, at T6, bacteria associated with mastitis were found in all the samples included in the study, except those collected from quarters treated with antibiotics, all of which became negative at microbiological culture at T6, with only one exception.

10.1371/journal.pone.0210204.t001

###### Microbiological culture results for each treatment group.

![](pone.0210204.t001){#pone.0210204.t001g}

                                                                T0       T6
  ------------------------------------------------------------- -------- --------
  **PBS treated**                                               **17**   **17**
  Staphylococcus aureus                                         **9**    **7**
  Coagulase-negative Staphylococci                              **4**    **3**
  Streptococcus agalactiae                                      **1**    **0**
  Staphylococcus aureus / Streptococcus agalactiae              **2**    **3**
  Coagulase-negative Staphylococci / Streptococcus agalactiae   **1**    **1**
  Negative                                                      **0**    **3**
  **LAB treated**                                               **15**   **15**
  Staphylococcus aureus                                         **9**    **9**
  Coagulase-negative Staphylococci                              **3**    **2**
  Streptococcus agalactiae                                      **3**    **0**
  Staphylococcus aureus / Streptococcus agalactiae              **0**    **2**
  Coagulase-negative Staphylococci / Streptococcus agalactiae   **0**    **2**
  Negative                                                      **0**    **0**
  **Ab treated**                                                **11**   **11**
  Staphylococcus aureus                                         **8**    **1**
  Coagulase-negative Staphylococci                              **2**    **0**
  Streptococcus agalactiae                                      **0**    **0**
  Staphylococcus aureus / Streptococcus agalactiae              **0**    **0**
  Coagulase-negative Staphylococci / Streptococcus agalactiae   **1**    **0**
  Negative                                                      **0**    **10**

PBS: quarters treated with sterile PBS only, LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, as described in Material and Methods. T0: pre-treatment time; T6: time at 6 days post treatment.

Somatic Cell Counts were measured at T-29, T-21, T-15, T-7 and T0, with the aim to monitor the microbial status of each quarter and identify those that would be included in the study, and T1, T2, and T6, to assess the effects of the treatment. All quarters challenged with inactivated *Lactobacillus rhamnosus* showed an increase in SCC. In individual quarters, elevation of SCC median reached its peak 24h post inoculation and then decreased afterward ([Fig 1](#pone.0210204.g001){ref-type="fig"}). PBS-infused control quarters showed a significant increase in SCC as compared with prechallenge levels starting from T1, and increased after T2. Antibiotic treated quarters showed an increase in SCC starting from T1 and further increases at T2. At T6, the SCC were decreased at the T0 level in all the three groups of samples.

![Somatic cell count in response to challenge with LAB, Ab and PBS.\
Median (line into the box), upper and lower quartiles (ends of the box) and highest and lowest values (extreme lines) are shown for challenged quarters. The bigger black points indicate outliers. \* indicates statistical significance at *p \< 0*.*05*.](pone.0210204.g001){#pone.0210204.g001}

Ion Torrent output: Sequences results after filtering procedures {#sec012}
----------------------------------------------------------------

The sequencing of 43 samples produced a total of 9,468,300 sequences and 4,039 features were obtained (with a mean of 112,717.85, a minimum of 9,778 and a maximum of 500,775 sequences) after filtering.

Core microbiota and taxonomic profile analysis before and after the treatment {#sec013}
-----------------------------------------------------------------------------

The core microbiota of milk from water buffaloes affected by subclinical mastitis is composed of eight main phyla, namely *Acidobacteria*, *Actinobacteria*, *Bacteroidetes*, *Cyanobacteria*, *Firmicutes*, *Proteobacteria*, *Verrucomicrobia* and *\[Thermi\]*. Results are presented in [Fig 2](#pone.0210204.g002){ref-type="fig"} and [Table 2](#pone.0210204.t002){ref-type="table"}. The milk microbiota was dominated by Firmicutes (mean of 60.9% at T0) and Proteobacteria (mean of 18.8% at T0). Treatment with *Lactobacillus rhamnosus* and PBS did not induce any major change from T0 to T6, with the exception of *\[Thermi\]*. On the contrary, treatment with Ab induced a decrease of Firmicutes (from 61.8% at T0 to 26.7% at T6), and an increase of Proteobacteria (from 13.8% at T0 to 30.8% at T6) and Actinobacteria (from 13.8% at T0 to 28.5% at T6). Comparing the relative abundance of bacterial phyla at T6 between different treatments, no differences were found between treatment with PBS and treatment with *Lactobacillus rhamnosus*. On the contrary, several differences were found between milk microbiota from quarters treated with *Lactobacillus rhamnosus* and Ab in the relative abundance of *Acidobacteria*, *Cyanobacteria and Firmicutes*. Differences were also found between milk quarters treated with PBS and Ab, in the relative abundance of *Actinobacteria* and *Firmicutes*.

![Water buffalo milk taxonomic profile at phylum level.\
LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, PBS: quarters treated with sterile PBS only. T0: time zero; T6: time at 6 days post treatment.](pone.0210204.g002){#pone.0210204.g002}

10.1371/journal.pone.0210204.t002

###### Relative abundance of microbiota taxa at phylum level.

![](pone.0210204.t002){#pone.0210204.t002g}

                      *Relative abundance frequencies*                                                                            
  ------------------- ---------------------------------- ------- ------- ------- ------- ------- ---- ------ ------- ---- ------- ---------
  *Acidobacteria*     0,3%                               0,3%    1,2%    0,2%    0,0%    0,0%    ns   ns     ns      ns   ns      ns
  *Actinobacteria*    11,7%                              14,2%   9,5%    9,9%    13,8%   28,5%   ns   ns     0,01    ns   0,002   \<0,001
  *Bacteroidetes*     3,9%                               6,3%    4,3%    4,7%    6,5%    11,4%   ns   ns     ns      ns   ns      ns
  *Cyanobacteria*     1,8%                               0,0%    0,1%    0,1%    0,7%    0,0%    ns   ns     ns      ns   ns      0,01
  *Firmicutes*        53,0%                              48,9%   68,1%   66,7%   61,8%   26,7%   ns   ns     0,005   ns   0,01    0.01
  *Proteobacteria*    27,9%                              28,6%   14,7%   17,5%   13,8%   30,8%   ns   ns     0,04    ns   ns      ns
  *Verrucomicrobia*   0,3%                               0,2%    0,3%    0,2%    0,7%    0,5%    ns   ns     ns      ns   ns      ns
  *\[Thermi\]*        0,0%                               0,0%    0,5%    0,0%    0,6%    1,0%    ns   0,03   ns      ns   ns      ns
  *Other*             1,1%                               1.5%    1,3%    0,6%    2,1%    1,0%    ns   ns     ns      ns   ns      ns

LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, PBS: quarters treated with sterile PBS only. T0: time zero; T6: time at 6 days post treatment

No core microbiota was present at family level. The main families found in milk microbiota at T0 were *Staphylococcaceae* (mean of 40.3%), followed by *Streptococcaceae* (mean of 5.8%), *Moraxellaceae* (mean of 5.2%), *Ruminococcaceae* (mean of 3.2%) and *Corynebacteriaceae* (mean of 4.4%). Taxonomic and statistical results at family level are shown in [S1 Table](#pone.0210204.s001){ref-type="supplementary-material"} and [S1 Fig](#pone.0210204.s003){ref-type="supplementary-material"} (relative abundance of almost 1%). PBS treatment did not cause significant milk microbiota alterations except for *Enterobacteriaceae* and *Rhodobacteriaceae*. Similarly, *Lactobacillus rhamnosus* treatment induced only an increase of *Pseudomonadaceae* (from 1.5% at T0 to 5.1% at T6). The main changes were present in antibiotic group at T6, where an increase of *Micrococcaceae* (from 0.9% at T0 to 3% at T6), *Bradyrhizobiaceae* (from 0.2% at T0 to 1.4% at T6), *Methylobacteriaceae* (from 1.1% at T0 to 6.7% at T6) and *Rhodocyclaceae* (from 0.1% at T0 to 1.2% at T6) was observed. A decrease of *Staphylococcaceae* (from 42.5% at T0 to 7.5% at T6) was also observed, even if the difference was not statistically significant. Comparing the relative abundance of taxa at family level among groups at T6, no differences were found between Ab and PBS groups except for *Microbacteriaceae* and *Cytophagaceae* and no major changes between *Lactobacillus rhamnosus* and PBS groups, except for *Peptostreptococcaceae* and *Comamonadaceae*. On the contrary, several changes were present between *Lactobacillus rhamnosus* and Ab microbiota at T6 showing differences in relative abundance (RA) of *Micrococcaceae*, *Propionibacteriaceae*, *Staphylococcaceae*, *Peptostreptococcaceae*, and *Comamonadaceae*.

It was not possible to identify any core microbiota at genus level. Taxonomic and statistical results at genus level were shown in [Table 3](#pone.0210204.t003){ref-type="table"} and [Fig 3](#pone.0210204.g003){ref-type="fig"} (relative abundance of almost 1%). Family level was indicated where genus level could not be reached. Milk samples at T0 were dominated by *Staphylococcus* (mean of 40%), followed by *Streptococcus* (mean of 9%), *Acinetobacter* (mean of 4.6%), *Corynebacterium* (mean of 4%) and *Propionibacterium* (mean of 2.3%). No changes were detected after PBS treatment. The main statistically significant changes after *Lactobacillus rhamnosus* treatment were identified as an increase of the RA of *Pseudomonas* from 1% at T0 to 4% at T6 and a minor increase of 5-7N15. As expected, major changes were found after Ab treatment, which induced a decrease of *Staphylococcus* from 41% at T0 to 3% at T6. A statistically significant increase of *Methylobacterium* was also found (from 1% at T0 to 6% at T6). Comparing the relative abundance of taxa at genus level among groups at T6, negligible changes were detected between PBS and *Lactobacillus rhamnosus* groups as well as between PBS and Ab groups. More genera differed between *Lactobacillus rhamnosus* and Ab microbiota, namely *Staphylococcus*, *Propionibacterium* and *5-7N15*.

![Water buffalo milk taxonomic profile at family/genus level (relative abundance of almost 1%).\
LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, PBS: quarters treated with sterile PBS only, as described in Material and Methods. T0: time zero; T6: time at 6 days post treatment.](pone.0210204.g003){#pone.0210204.g003}

10.1371/journal.pone.0210204.t003

###### Relative abundance of microbiota taxa at family/genus level.

![](pone.0210204.t003){#pone.0210204.t003g}

                          *Relative abundance frequencies*   *p-value (where p \< 0*.*05)*                                                           
  ----------------------- ---------------------------------- ------------------------------- ----- ----- ----- ----- ---- ------- ------ ---- ------ -------
  **Deinococcus**         0%                                 0%                              0%    0%    1%    0%    ns   ns      ns     ns   ns     ns
  **Corynebacterium**     3%                                 5%                              3%    4%    6%    7%    ns   ns      ns     ns   ns     0,04
  **Dietzia**             0%                                 1%                              1%    0%    1%    1%    ns   ns      ns     ns   ns     ns
  **Nesterenkonia**       1%                                 1%                              0%    0%    0%    1%    ns   ns      ns     ns   ns     ns
  **Rhodococcus**         0%                                 0%                              0%    0%    0%    1%    ns   ns      ns     ns   ns     ns
  **Propionibacterium**   3%                                 2%                              2%    2%    3%    10%   ns   ns      ns     ns   ns     0,002
  **CF231**               0%                                 0%                              0%    0%    1%    0%    ns   ns      0.03   ns   ns     ns
  **5-7N15**              0%                                 1%                              0%    1%    0%    0%    ns   0.01    ns     ns   ns     ns
  **Hymenobacter**        0%                                 0%                              0%    0%    0%    6%    ns   ns      ns     ns   ns     ns
  **Chryseobacterium**    0%                                 0%                              0%    0%    0%    1%    ns   ns      ns     ns   0,04   ns
  **Natronobacillus**     0%                                 1%                              0%    1%    1%    1%    ns   ns      ns     ns   ns     ns
  **Lysinibacillus**      0%                                 1%                              0%    0%    0%    0%    ns   ns      ns     ns   ns     ns
  **Solibacillus**        0%                                 2%                              1%    1%    0%    1%    ns   ns      ns     ns   ns     ns
  **Jeotgalicoccus**      0%                                 1%                              1%    1%    1%    2%    ns   ns      ns     ns   ns     ns
  **Salinicoccus**        0%                                 1%                              0%    0%    1%    2%    ns   ns      ns     ns   ns     ns
  **Staphylococcus**      33%                                25%                             43%   45%   41%   3%    ns   ns      0.03   ns   ns     0,01
  **Alkalibacterium**     0%                                 1%                              0%    0%    1%    1%    ns   ns      ns     ns   ns     ns
  **Facklamia**           0%                                 0%                              1%    0%    0%    0%    ns   ns      ns     ns   ns     ns
  **Granulicatella**      0%                                 0%                              0%    0%    0%    1%    ns   ns      ns     ns   ns     ns
  **Streptococcus**       6%                                 6%                              11%   8%    1%    2%    ns   ns      ns     ns   ns     ns
  **Bradyrhizobium**      1%                                 0%                              1%    0%    0%    1%    ns   ns      ns     ns   ns     ns
  **Methylobacterium**    1%                                 5%                              1%    1%    1%    6%    ns   ns      0,02   ns   ns     ns
  **Sphingomonas**        0%                                 0%                              0%    1%    1%    3%    ns   ns      ns     ns   ns     ns
  **Delftia**             0%                                 1%                              1%    0%    0%    1%    ns   ns      ns     ns   ns     ns
  **Hydrogenophilus**     1%                                 1%                              0%    1%    0%    1%    ns   ns      ns     ns   ns     ns
  **Escherichia**         4%                                 0%                              2%    0%    2%    1%    ns   ns      ns     ns   ns     ns
  **Halomonas**           1%                                 1%                              0%    2%    1%    2%    ns   ns      ns     ns   ns     ns
  **Acinetobacter**       10%                                6%                              3%    2%    1%    2%    ns   ns      ns     ns   ns     ns
  **Psychrobacter**       1%                                 0%                              0%    0%    0%    0%    ns   ns      ns     ns   ns     ns
  **Pseudomonas**         2%                                 3%                              1%    4%    1%    2%    ns   0,007   ns     ns   ns     ns

LAB: quarters treated with inactivated culture of Lactobacillus rhamnosus only, Ab: quarters treated with antibiotics, PBS: quarters treated with sterile PBS only, as described in Material and Methods. T0: time zero; T6: time at 6 days post treatment

Discriminant analysis following treatment {#sec014}
-----------------------------------------

Considering the effect of the treatment on microbiota, alpha diversity showed differences between Ab- and LAB-treated groups at richness level, where a decrease of 85.4 and an increase of 80.3 observed species was observed, respectively (*p* = 0.03). No modification of richness or evenness was observed comparing microbiota T0 vs T6 within the same group.

Beta diversity analysis showed differences on the basis of the weighted UniFrac distance matrix. Modification in microbiota was observed only after Ab treatment, whose groups at T0 and T6 were discriminated by the axis 2 from PCoA plot (*p* = 0.04): samples moved across the axis 2 in the same direction between T0 and T6, suggesting that these samples experienced the same directional shift in terms of microbiota structure, even if the magnitude or the final composition could not be the same. The effect of the treatment, plotted in [Fig 4](#pone.0210204.g004){ref-type="fig"}, showed that the Ab effect on the microbiota structure was greater than the *Lactobacillus rhamnosus* effect (*p* = 0.001), which was in turn smaller than the PBS effect (*p* = 0.003).

![Boxplots show quartile distribution of weighted UniFrac distances between each group diversity after LAB, Ab and PBS treatment.\
Statistical significant differences were found between Ab and LAB (*p* = 0.001) and LAB and PBS (*p* = 0.003). LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, PBS: quarters treated with sterile PBS only, as described in Material and Methods.](pone.0210204.g004){#pone.0210204.g004}

Discussion {#sec015}
==========

Probiotics have been used as a corrective measure to re-equilibrate the microbiota during mastitis, with contradictory results. Remarkably, the effects of GRAS on microbiota as determined by culture independent methods has not been investigated so far. In this study, we reported the effects of an *in vivo* treatment on mammary glands with inactivated cultures of *Lactobacillus rhamnosus* of water buffaloes affected by subclinical mastitis in order to analyze the change in microbiota structure and evaluate the use of this GRAS as alternative strategy to the use of antibiotics. To the best of the knowledge of the authors, this was the first study using *Lactobacillus rhamnosu*s in an *in vivo* study on mammary gland. The scientific background behind the experimental design was that *Lactobacillus rhamnosus*, in combination with other Lactic acid bacteria, was able to modulate the pathogenic environment in the vaginal tract by regulating *Escherichia coli* infection and inflammation of the bovine endometrium \[[@pone.0210204.ref029]\]. At least so far, live cultures of probiotic were not found to improve mouse \[[@pone.0210204.ref046]\], cow \[[@pone.0210204.ref018],[@pone.0210204.ref022],[@pone.0210204.ref047]\] or ewe \[[@pone.0210204.ref024]\] mastitis. On the contrary, most of the Lactobacilli and Lactococci strains used so far for *in vivo* studies have been demonstrated to exert a pro-inflammatory activity: *Lactococcus lactis*, for example, is regarded as a pathogen causing mastitis \[[@pone.0210204.ref048],[@pone.0210204.ref049]\]. The cultures used for *in vivo* challenging were previously inactivated with heat. This procedure was carried out to prevent any potential proinflammatory activity related to *in vivo* treatment with GRAS, as previously reported \[[@pone.0210204.ref050]\] which would have probably induced an acute inflammation, eventually switching the clinical status from sub-clinical to clinical mastitis. Moreover, a potential interference on the microbiota analysis of an uncontrolled overgrowth of living lactobacilli culture after inoculation in the mammary gland was envisaged, which would probably prevail over the other bacterial species, interfering with the detection of other microbial species.

We found that, although inactivated, the intramammary inoculation of LAB had a significant chemotactic effect toward leukocytes, as shown by the increase of milk somatic cells after 1 day from the inoculation of LAB. Intramammary gland treatment with PBS induces an increase of SCC as well, but two days after inoculation: interestingly, this result is consistent with what has been previously reported in a similar study using sterile PBS as negative control \[[@pone.0210204.ref051]\]. Treatment with antibiotics also elicited a chemotactic effect as well, although the increase of SCC is more limited as compared with LAB. The present results confirmed that intramammary inoculation of either bacteria, PBS or antibiotics triggers an inflammatory response, as demonstrated by the increase of SCC.

The microbiota of milk from affected animals largely corresponds to what has been previously reported \[[@pone.0210204.ref041]\] with some exceptions; among the others, the relative abundance of *Psycrobacter* and *Pseudomonas*, which were at 8.79% and 14.45% in the previous study, ranged in the present study from 2% to 4% and from 1% to 2%, respectively. S*B53* was not found as well, whereas its RA was at 3.7% in previous reports. These differences may be explained by the fact that sub-clinical mastitis can be caused by intramammary infection by a heterogeneous group of microorganisms, and the relative abundance of each microbial population may therefore be heterogeneous as well. No families nor genera were shared among subclinical mastitis samples, confirming that microbiota varies more in sub-clinical mastitis than healthy individuals as previously reported \[[@pone.0210204.ref041],[@pone.0210204.ref052]\].

No major changes in microbiological cultures were found in milk quarters treated with LAB and PBS. As expected, the milk from quarters treated with antibiotic became negative at microbiological count, with one exception.

After treatment with inactivated Lactobacillus *rhamnosus*, we found an increase of up to 4% in the relative abundance of *Pseudomonas*. This finding is interesting, because the relative abundance of *Pseudomonas* genus was found to be associated to mastitis in water buffalo in our previous report \[[@pone.0210204.ref041]\], and is already known as mastitis pathogen in cow \[[@pone.0210204.ref053]\], sheep \[[@pone.0210204.ref054]\] and goats \[[@pone.0210204.ref055]\]. We may therefore hypothesize that the inoculation of LAB, though inactivated, may unbalance the microbiota of water buffalo by increasing the relative abundance of genus involved in the development of mastitis. It must also be said that the effects on microbiota of sterile PBS was more evident than the effects of inactivated cultures of LAB. This results may provide suggestions about the use of PBS as negative control for *in vivo* studies on mammary gland.

Other major finding was that the treatment with antibiotics increased at T6 the relative abundance of *Methylobacterium*, which was not found in milk treated with *Lactobacillus rhamnosus* and PBS. *Methylobacterium* forms biofilms and can develop resistance to high temperatures, drying, and disinfecting agents \[[@pone.0210204.ref056]\], which features may partially explain the growth capability of this genus after antibiotic treatment. These results supported in water buffalo the hypothesis that has been recently advanced in dairy cow that the mammary gland hosts a resilient microbiome that can reestablish after treatment with antibiotics \[[@pone.0210204.ref057]\].

Given the background that *Lactobacillus rhamnosus* culture was inactivated, and it induced an extravasation of leukocytes from blood toward the milk, we may speculate that the few modification of microbiota are determined by the intervening WBC, that are activated by the PAMP exposed on the surface of killed bacteria.

Interestingly, we found that no paracrine effect was present within the mammary glands: in all animals with subclincal mastitis quarters treated with antibiotic and other subclinical mastitis quarters treated with *Lactobacillus rhamnosus* or PBS, only the antibiotic-treated quarter became MC negative. About the others within the same mammary gland, they did not change or became MC positive at T6, suggesting the independence of every single quarter.

Conclusions {#sec016}
===========

This is the first experiment on water buffaloes, and in ruminants in general, that aimed to investigate the effect of *Lactobacillus rhamnosus* on subclinical mastitis. We demonstrated that the *in vivo* intramammary treatment with *Lactobacillus rhamnosus* has a transient pro-inflammatory activity as assessed by the SCC and is capable to modify the microbiota of milk after six days from inoculation, albeit slightly, even when the bacterial cultures were heat inactivated. This study confirmed the potential pro-inflammatory activity of GRAS bacteria, and suggests that careful approaches are needed for its *in vivo* use.

Supporting information {#sec017}
======================

###### Relative abundance (\> 1%) of microbiota taxa at family level.

PBS: quarters treated with sterile PBS only, LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, AB: quarters treated with antibiotics, as described in Material and Methods. T0: time zero; T6: time at 6 days post treatment.

(DOCX)

###### 

Click here for additional data file.

###### Sampling time, microbiological result, SCC and group for each quarter included in the study.

MC: Microbiological count. SCC (Somatic Cell Count) is x 1000. NA: not Assessed.

(DOCX)

###### 

Click here for additional data file.

###### Water buffalo milk taxonomic profile at family level (relative abundance of \> 1%).

PBS: quarters treated with sterile PBS only, LAB: quarters treated with inactivated culture of *Lactobacillus rhamnosus* only, Ab: quarters treated with antibiotics, as described in Material and Methods. T0: time zero; T6: time at 6 days post treatment.

(TIF)

###### 

Click here for additional data file.
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